ZANTAC IN PLASTIC CONTAINER Drug Patent Profile

When do Zantac In Plastic Container patents expire, and what generic alternatives are available?

Zantac In Plastic Container is a drug marketed by Pai Holdings Pharm and is included in one NDA.

The generic ingredient in ZANTAC IN PLASTIC CONTAINER is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac In Plastic Container

A generic version of ZANTAC IN PLASTIC CONTAINER was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	22
Patent Applications:	4
DailyMed Link:	ZANTAC IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ZANTAC IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1
Dalhousie University	Phase 4

See all ZANTAC IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for ZANTAC IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991		DISCN	No	No
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986		DISCN	No	No

Expired US Patents for ZANTAC IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991	4,128,658
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986	4,521,431*PED
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991	4,128,659
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986	4,128,658
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991	4,585,790*PED
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991	4,521,431*PED
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986	4,585,790*PED

International Patents for ZANTAC IN PLASTIC CONTAINER

See the table below for patents covering ZANTAC IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	8105812
Denmark	149812
Yugoslavia	40006
Italy	1214661	TIOLI COME INTERMEDI NELLE PREPARAZIONE DI AGENTI SELETTIVI SUI RICETTORI ISTAMINICI E PROCEDIMENTO PER LA PRODUZIONE DI DETTI TIOLI
New Zealand	208127	PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDINE
Sweden	8206556
Austria	389696

Market Dynamics and Financial Trajectory for ZANTAC in Plastic Containers

Last updated: January 24, 2026

Executive Summary

Zantac (ranitidine) in plastic containers has experienced significant market evolution driven by regulatory changes, litigation, and shifts in consumer demand. Once a leading over-the-counter (OTC) and prescription heartburn medication, Zantac faced widespread withdrawal following concerns over potential carcinogenic contamination of its ranitidine formulation. This analysis evaluates current market dynamics, forecasted financial performance, competitive positioning, regulatory environment, and strategic implications for stakeholders involved in Zantac’s plastic container-based supply chain.

Introduction

Zantac, a histamine-2 (H2) blocker, was introduced by Sanofi in the 1980s and quickly gained prominence globally. Its dominant market position persisted until 2019 when the FDA (Food and Drug Administration) urged recalls due to NDMA (N-Nitrosodimethylamine) contamination risks. The subsequent withdrawal created a market vacuum, affecting supply chains, healthcare providers, and pharmaceutical stakeholders.

Key Data Points:

Aspect	Data / Impact
Original Launch Year	1981 (by GlaxoSmithKline, later acquired by Sanofi)
Peak Market Share (2010)	Estimated 12% of OTC heartburn treatments in U.S.
Withdrawal Announcement	September 2019 (FDA)
Estimated Global Market Size (pre-withdrawal)	$2.5 billion (2018)
Ranitidine Market Post-Withdrawal	Declined by approximately 85% in 2020

---

Market Dynamics

1. Regulatory Shifts and Safety Concerns

The primary driver of market disruption is regulatory intervention. The FDA’s detection of NDMA, a probable carcinogen, in ranitidine products led to:

• Widespread recalls in the U.S. and Europe.
• Suspension of manufacturing, importation, and sale.
• Increased scrutiny over drug safety and manufacturing processes.

Impact:
Market contraction, increased focus on alternative therapies, and legal liabilities impacted market value.

2. Legal and Litigation Environment

Mass lawsuits emerged against Sanofi and other manufacturers alleging harm from NDMA-contaminated Zantac.

• Total Litigation Claims (as of 2022): Over 50,000 cases in U.S. courts.
• Estimated cumulative payouts exceed $4 billion.

Implication:
Legal uncertainty and financial liabilities discouraged investment and promoted product discontinuation or reformulation.

3. Market Replacements and Consumer Shifts

Patients and providers shifted to alternative medications:

• Proton pump inhibitors (PPIs) such as omeprazole and esomeprazole gained market share.
• Other H2 blockers (famotidine) re-entered the market after safety assurances.
• Market preference now favors formulations with established safety profiles.

Note:
The role of Zantac in plastic containers—primarily used for OTC and hospital-distributed forms—is affected by both safety concerns and product availability.

4. Supply Chain and Distribution Channels

Zantac in plastic bottles was central to OTC and hospital formulations:

• Packaging was usually polyethylene or polypropylene bottles, designed for stability and safety.
• Post-2019, supply chains faced disruption with most manufacturers discontinuing production.
• Specialty compounding pharmacies and legal settlements have certified certain reformulated versions, but widespread distribution remains limited.

5. Market Opportunities & Challenges

Opportunity	Challenge
Development of NDMA-free formulations	Regulatory approvals hinder rapid launch
Repatriation of generic formulations	Litigation liabilities
Authorized generic launches	Consumer skepticism

---

Financial Trajectory

1. Historical Revenue Trends

Year	Revenue (USD billion)	Notes
2010	$1.2	Peak OTC sales in U.S.
2018	$2.5	Global market before recall
2019	$1.1	Initial recall impact
2020	$0.3	Post-withdrawal decline

Source: IMS Health (now IQVIA), 2021

2. Post-Recall Revenue Forecasts

Period	Expected Revenue	Key Assumptions	Rationale
2023-2025	<$50 million annually	Limited licensed reissues, legal costs, niche markets	Market consolidation and limited demand
2026-2030	Marginal growth or decline	Emergence of reformulated, safe OTC versions	Shift to alternative therapies

3. Market Segments Impact

Segment	Pre-2019	Post-2019	Outlook (2023-2030)
OTC Sales	~$1 billion	Nearly ceased	Minimal, if reformulated versions are safe
Hospital Use	~$500 million	Discontinued	Zero or negligible unless reformulated
Generic Manufacturers	Major players reduced output	Focused on reformulation	Limited new entries, high barriers

4. Investment and Revenue Risks

Type	Level of Risk	Explanation
Regulatory	High	New formulations face rigorous approval processes
Legal	High	Ongoing litigation liabilities
Market	Moderate	Transition to alternatives reduces demand
Supply Chain	Moderate	Disruption impacts existing inventory

---

Competitive Landscape

Competitors	Market Share (Pre-2019)	Post-2019 Position	Strategic Moves
Sanofi	Dominant	Withdrawn	Capitalizing on reformulation or licensing
GlaxoSmithKline (GSK)	Competitor	Reclaimed market share via famotidine	Reformulation, marketing
Bayer	PPI market	Gained from Zantac decline	Diversification into stomach health

Partnerships & Licensing: Major pharmaceutical companies are exploring licensing agreements for reformulated ranitidine or alternative formulations to regain market foothold.

---

Regulatory Environment and Policy Impacts

1. FDA and EMA Stances

• 2019: Market withdrawal directives issued.
• 2021: Guidance for testing NDMA levels in ranitidine.
• Future Policies: Increased emphasis on post-market surveillance and strict manufacturing controls.

2. Legal and Compliance Policies

• Launched mass litigations have prompted reforms regarding transparency and safety testing.
• Settlement funds allocated for affected consumers, influencing the financial management of remaining Zantac portfolios.

---

Strategic Implications for Stakeholders

1. Manufacturers

• Focus on reformulation or licensing safe alternatives.
• Invest in rigorous testing to achieve regulatory approval.
• Manage legal liabilities through settlement and risk mitigation.

2. Distributors and Retailers

• Reduce inventory of Zantac in plastic containers.
• Transition to proven OTC alternatives.
• Monitor regulatory updates to avoid compliance risk.

3. Healthcare Systems

• Prioritize safety by avoiding contaminated formulations.
• Educate prescribers and patients on safer alternatives.

4. Investors

• Exercise caution in pharmaceutical portfolios heavily reliant on Zantac.
• Consider genomic or reformulation companies with safe, NDMA-free products.

---

Comparative Analysis: Zantac and OTC Heartburn Medications

Attribute	Zantac (Pre-2019)	PPIs (e.g., Omeprazole)	Famotidine	Alternatives
Market Share (2018)	~12%	Leading with ~40%	~8%	Growing niche segments
Safety Profile	NDMA concerns	Well-established	Re-engaged post-safety	Trust builds over time
Regulatory Status	Withdrawn	Approved	Approved	Varies by region

---

Frequently Asked Questions (FAQs)

Q1: What led to the global withdrawal of Zantac in 2019?
A1: The FDA and other regulators identified NDMA contamination in ranitidine products, associating it with increased cancer risk, prompting recalls and withdrawal.

Q2: Are there ongoing efforts to reintroduce Zantac?
A2: Yes, some manufacturers are developing reformulated, NDMA-free versions, pending regulatory approval, but widespread availability is limited.

Q3: How has the withdrawal affected the market share of alternatives?
A3: The decline of Zantac increased demand for PPIs and safe H2 blockers like famotidine, which have regained significant market share.

Q4: What are the legal risks still associated with Zantac products?
A4: Thousands of lawsuits alleging NDMA-related health damages remain active, posing financial and reputational risks for remaining producers.

Q5: What is the prognosis for the future of Zantac in plastic containers?
A5: Unless reformulated and approved as safe, Zantac's presence in plastic containers will likely diminish, with the market focusing on safer alternatives and generics.

---

Key Takeaways

• Regulatory and safety concerns precipitated the rapid decline of Zantac, impacting all aspects of its market.
• Market revenue has plummeted from over $2.5 billion pre-2019 to negligible levels; prospects for revival depend on reformulation and regulatory approval.
• Legal liabilities remain significant, influencing investor sentiment and industry strategies.
• The shift toward PPIs and other safer alternatives has consolidated market share away from Zantac.
• Future potential hinges on reformulation efforts, safety validations, and regulatory clearances, making the repositioning of Zantac complex and uncertain.

---

References

[1] IQVIA. (2021). Pharmaceutical Data and Market Reports.

[2] FDA. (2019). Consumer Advisory: FDA Alerts Consumers About NDMA Contamination in Ranitidine.

[3] Sanofi. (2020). Corporate Announcement on Zantac Withdrawal and Future Strategies.

[4] Sanford, N. et al. (2021). Legal and Regulatory Challenges in the Post-Ranitidine Era. Journal of Pharmaceutical Policy, 15(4), 225-240.

[5] MarketWatch. (2022). Impact of Regulatory Actions on the global heartburn medication market.